Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

Stephen E. Jones, Michael A. Savin, Frankie Ann Holmes, Joyce A. O'Shaughnessy, Joanne L. Blum, Svetislava Vukelja, Kristi J. McIntyre, John E. Pippen, James H. Bordelon, Robert Kirby, John Sandbach, William J. Hyman, Pankaj Khandelwal, Angel G. Negron, Donald A. Richards, Stephen P. Anthony, Robert G. Mennel, Kristi A. Boehm, Walter G. Meyer, Lina Asmar

Research output: Contribution to journalArticle

392 Citations (Scopus)

Abstract

Purpose: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively; n = 510) or TC (75 and 600 mg/m2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

Original languageEnglish (US)
Pages (from-to)5381-5387
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number34
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

docetaxel
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Disease-Free Survival
Therapeutics
Adjuvant Chemotherapy
Survival Rate
Febrile Neutropenia
Myalgia
Arthralgia
Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. / Jones, Stephen E.; Savin, Michael A.; Holmes, Frankie Ann; O'Shaughnessy, Joyce A.; Blum, Joanne L.; Vukelja, Svetislava; McIntyre, Kristi J.; Pippen, John E.; Bordelon, James H.; Kirby, Robert; Sandbach, John; Hyman, William J.; Khandelwal, Pankaj; Negron, Angel G.; Richards, Donald A.; Anthony, Stephen P.; Mennel, Robert G.; Boehm, Kristi A.; Meyer, Walter G.; Asmar, Lina.

In: Journal of Clinical Oncology, Vol. 24, No. 34, 01.12.2006, p. 5381-5387.

Research output: Contribution to journalArticle

Jones, SE, Savin, MA, Holmes, FA, O'Shaughnessy, JA, Blum, JL, Vukelja, S, McIntyre, KJ, Pippen, JE, Bordelon, JH, Kirby, R, Sandbach, J, Hyman, WJ, Khandelwal, P, Negron, AG, Richards, DA, Anthony, SP, Mennel, RG, Boehm, KA, Meyer, WG & Asmar, L 2006, 'Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer', Journal of Clinical Oncology, vol. 24, no. 34, pp. 5381-5387. https://doi.org/10.1200/JCO.2006.06.5391
Jones, Stephen E. ; Savin, Michael A. ; Holmes, Frankie Ann ; O'Shaughnessy, Joyce A. ; Blum, Joanne L. ; Vukelja, Svetislava ; McIntyre, Kristi J. ; Pippen, John E. ; Bordelon, James H. ; Kirby, Robert ; Sandbach, John ; Hyman, William J. ; Khandelwal, Pankaj ; Negron, Angel G. ; Richards, Donald A. ; Anthony, Stephen P. ; Mennel, Robert G. ; Boehm, Kristi A. ; Meyer, Walter G. ; Asmar, Lina. / Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 34. pp. 5381-5387.
@article{2b0cccc4410b44448a939eb87d1b20f9,
title = "Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer",
abstract = "Purpose: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively; n = 510) or TC (75 and 600 mg/m2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86{\%} v80{\%}, respectively; hazard ratio [HR] = 0.67; 95{\%} CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90{\%} and 87{\%}, respectively (HR = 0.76; 95{\%} CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.",
author = "Jones, {Stephen E.} and Savin, {Michael A.} and Holmes, {Frankie Ann} and O'Shaughnessy, {Joyce A.} and Blum, {Joanne L.} and Svetislava Vukelja and McIntyre, {Kristi J.} and Pippen, {John E.} and Bordelon, {James H.} and Robert Kirby and John Sandbach and Hyman, {William J.} and Pankaj Khandelwal and Negron, {Angel G.} and Richards, {Donald A.} and Anthony, {Stephen P.} and Mennel, {Robert G.} and Boehm, {Kristi A.} and Meyer, {Walter G.} and Lina Asmar",
year = "2006",
month = "12",
day = "1",
doi = "10.1200/JCO.2006.06.5391",
language = "English (US)",
volume = "24",
pages = "5381--5387",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

TY - JOUR

T1 - Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

AU - Jones, Stephen E.

AU - Savin, Michael A.

AU - Holmes, Frankie Ann

AU - O'Shaughnessy, Joyce A.

AU - Blum, Joanne L.

AU - Vukelja, Svetislava

AU - McIntyre, Kristi J.

AU - Pippen, John E.

AU - Bordelon, James H.

AU - Kirby, Robert

AU - Sandbach, John

AU - Hyman, William J.

AU - Khandelwal, Pankaj

AU - Negron, Angel G.

AU - Richards, Donald A.

AU - Anthony, Stephen P.

AU - Mennel, Robert G.

AU - Boehm, Kristi A.

AU - Meyer, Walter G.

AU - Asmar, Lina

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively; n = 510) or TC (75 and 600 mg/m2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

AB - Purpose: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively; n = 510) or TC (75 and 600 mg/m2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

UR - http://www.scopus.com/inward/record.url?scp=34247270770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247270770&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.5391

DO - 10.1200/JCO.2006.06.5391

M3 - Article

C2 - 17135639

AN - SCOPUS:34247270770

VL - 24

SP - 5381

EP - 5387

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -